Related Experiment Videos
[Clinical experience with a second-generation cardioverter-defibrillator].
B J Meyer1, R Candinas, H O Gloor
1Abteilungen für Kardiologie, Universitätspital Zürich.
Schweizerische Medizinische Wochenschrift
|November 16, 1991
Summary
Second-generation implantable cardioverter defibrillators (ICDs) effectively treated malignant ventricular arrhythmias (MVA) in seven patients. The devices successfully managed ventricular fibrillation and tachycardia episodes, preventing further MVA recurrence in most cases.
Area of Science:
- Cardiology
- Biomedical Engineering
Context:
- Refractory malignant ventricular arrhythmias (MVA) pose a significant mortality risk.
- Second-generation implantable cardioverter defibrillators (ICDs) offer a therapeutic option for MVA management.
Purpose:
- To evaluate the efficacy and safety of second-generation ICDs (Telectronics Guardian 4202/4203) in patients with refractory MVA.
Summary:
- Seven patients (mean age 58.1) with ventricular fibrillation (VF) and/or ventricular tachycardia (VT) received ICDs.
- Mean follow-up was 10.1 months; successful defibrillation occurred in 2 patients, and 5 remained MVA-free.
- One device explantation due to tissue necrosis and false shock prevention by the reconfirmation algorithm were noted.
Impact:
- Second-generation ICDs demonstrate effectiveness in preventing MVA recurrence and reducing mortality.
- The study highlights the potential of ICDs in managing complex cardiac arrhythmias.
- Device performance and patient outcomes provide valuable data for clinical practice and future device development.